MedPlus Health Services Limited (MEDPLUS) Fair Value & Analysis
Healthcare · IN · Market cap ₹98.1B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price −8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹737.24 – ₹948.04 · fair‑value band ₹275.37 – ₹511.40 · the ₹816.95 price screens above the ₹393.38 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
MedPlus Health Services Limited (MEDPLUS) currently trades at ₹816.95, while our model-based Fair Value estimate is ₹393.38 — implying the stock looks roughly 51.8% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, MedPlus Health Services Limited generated revenue of ₹68.9B at a net margin of 3.2%. Revenue grew 23.5% year over year. It earns a return on equity of 11.8%. Net debt stands at ₹9.6B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
MedPlus Health Services Limited reported revenue of ₹68.9B in FY2026 versus ₹37.8B in FY2022, a compound +16.2%/yr. Reported net income was ₹2.2B in FY2026, compounding +23.1%/yr from FY2022.
Is MEDPLUS fairly valued? → Check now
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $4.26 | $6.93 | +63% |
| Alibaba Health Information Technology Limited ALBBY | $8.42 | $6.94 | -18% |
| Raia Drogasil S.A RADL3 | R$16.79 | R$20.39 | +21% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥29.07 | +47% |
| Clicks Group CLCGY | $28.55 | $41.54 | +45% |
| Sugi Holdings SGIPF | $16.29 | $29.89 | +83% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MedPlus Health Services Limited (MEDPLUS) undervalued?
What is the fair value of MEDPLUS?
What is the quality score of MEDPLUS?
What is the revenue of MedPlus Health Services Limited (MEDPLUS)?
What is the net profit margin of MEDPLUS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.